Pharma Update

Pipeline acceleration via partnering Deals of the past two years increasingly focused on clinical stage NMEs* TA NME Indication Partner Development stage P-CD19CD20-ALL01 B-cell malignancies Pre-clin. Phl POSEIDA THERAPEUTICS P-BCMA-ALLO1 Multiple myeloma Phl AR degrader mCRPC Jemincare Phl camonsertib Solid tumors REPARE Phl THERAPEUTICS KSQ-4279 Solid tumors OpRegen Geographic atrophy KSQ -==LINEAGE CELL THERAPEUTICS Phl Ph II ASO factor B IgAN IONIS Ph Il Ph III vixarelimab IPF & SSC-ILD KINIKSA Ph ll zilebesiran Oncology/Hematology Hypertension Ophthalmology 0 Alnylam PHARMACEUTICALS Ph ll Development stage at time of deal Positive proof of concept data Current development stage Immunology Cardiovascular & Metabolism *Table shows clinical stage NME deals completed 2021-2023 YTD; TA-therapeutic area; mCRPC=metastatic castrations-resistant prostate cancer; AR-androgen receptor; IgAN-immunuglobululin A nephropathy; ASO-antisense oligonucleotide; IPF-idiopathic pulmonary fibrosis; SSC-ILD-systemic sclerosis-interstitial lung disease Roche 31

View entire presentation